Overview

Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue

Status:
COMPLETED

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

Fatigue is a prevalent adverse event associated with systemic therapy using tyrosine kinase inhibitors (TKIs). Meldonium, a fatty acid oxidation inhibitor, modifies the carnitine pathway, a nutrient critical for fat metabolism. The World Anti-Doping Agency (WADA) classified meldonium as a banned substance due to its documented use by athletes aiming to enhance physical performance. In this study, the safety and preliminary efficacy of meldonium in treatment-related fatigue will be assessed.

Phase:

PHASE1

Details

Lead Sponsor:

Kidney Cancer Research Bureau

Treatments:

3-(2,2,2-trimethylhydrazine)propionate